An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy

Click to increase image sizeClick to decrease image size

Declaration of interest

G Borgia is a Consultant for Abbvie and has received grants from Abbvie, Merck Sharp & Dohme, Pfizer.

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

One reviewer is a consultant for Gilead, AbbVie and Merck. Other peer reviewers on this manuscript have no relevant financial or other relationships to disclose.